Vivani Medical IncNASDAQ:VANI
- LAST PRICE1.4250
- TODAY'S CHANGE (%)0.0550 (4.0146%)
- Bid / Lots1.4200/ 2
- Ask / Lots1.4300/ 5
- Open / Previous Close1.3700 / 1.3700
- Day Range
- 52 Week Range
- Volume169,159
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VANI |
|---|---|---|
| 09:32 ET | 3144 | 1.37 |
| 09:33 ET | 550 | 1.38 |
| 09:35 ET | 1200 | 1.375 |
| 09:37 ET | 300 | 1.385 |
| 09:39 ET | 1059 | 1.3806 |
| 09:42 ET | 500 | 1.375 |
| 09:44 ET | 2090 | 1.3701 |
| 09:50 ET | 100 | 1.38 |
| 09:51 ET | 1200 | 1.375 |
| 09:53 ET | 600 | 1.375 |
| 09:55 ET | 100 | 1.375 |
| 09:57 ET | 600 | 1.38 |
| 10:04 ET | 400 | 1.3756 |
| 10:06 ET | 2100 | 1.37 |
| 10:08 ET | 100 | 1.37 |
| 10:15 ET | 520 | 1.3712 |
| 10:22 ET | 6429 | 1.365 |
| 10:27 ET | 37135 | 1.42 |
| 10:31 ET | 3004 | 1.415 |
| 10:33 ET | 585 | 1.4107 |
| 10:36 ET | 8000 | 1.43 |
| 10:38 ET | 630 | 1.4392 |
| 10:40 ET | 1000 | 1.4314 |
| 10:42 ET | 500 | 1.4307 |
| 10:56 ET | 250 | 1.43 |
| 10:58 ET | 3600 | 1.435 |
| 11:00 ET | 1000 | 1.435 |
| 11:02 ET | 150 | 1.4309 |
| 11:07 ET | 4469 | 1.445 |
| 11:09 ET | 700 | 1.4444 |
| 11:14 ET | 100 | 1.4406 |
| 11:16 ET | 1952 | 1.425 |
| 11:18 ET | 662 | 1.42 |
| 11:20 ET | 600 | 1.4207 |
| 11:23 ET | 3100 | 1.425 |
| 11:25 ET | 9734 | 1.43 |
| 11:36 ET | 500 | 1.4317 |
| 11:39 ET | 407 | 1.432 |
| 11:41 ET | 600 | 1.445 |
| 11:43 ET | 500 | 1.449 |
| 11:45 ET | 527 | 1.445 |
| 11:50 ET | 300 | 1.445 |
| 11:56 ET | 200 | 1.4413 |
| 11:59 ET | 30484 | 1.445 |
| 12:03 ET | 712 | 1.445 |
| 12:14 ET | 200 | 1.442 |
| 12:17 ET | 200 | 1.445 |
| 12:19 ET | 10433 | 1.445 |
| 12:21 ET | 4023 | 1.445 |
| 12:24 ET | 666 | 1.44 |
| 12:26 ET | 349 | 1.442 |
| 12:28 ET | 2200 | 1.44 |
| 12:30 ET | 3100 | 1.44 |
| 12:32 ET | 3355 | 1.435 |
| 12:33 ET | 200 | 1.438 |
| 12:42 ET | 3628 | 1.4206 |
| 12:50 ET | 100 | 1.425 |
Nov 20, 2024
*DJ Vivani Medical Unit Cortigent Expects IPO of 1.5M Shrs to Price at $10 Each, from 5:25PM ET on Wednesday Nov 20, 2024 by Dow Jones
5:25PM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 13, 2024
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
DJ Vivani Medical Initiated at Buy by HC Wainwright & Co., from 3:46PM ET on Thursday Nov 07, 2024 by Dow Jones
3:46PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 29, 2024
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now, from 7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vivani Medical Inc | 79.4M | -3.1x | --- |
Monogram Technologies Inc | 67.6M | -5.5x | --- |
InspireMD Inc | 69.1M | -3.8x | --- |
Work Medical Technology Group Ltd | 84.3M | 744.8x | --- |
Baird Medical Investment Holdings Ltd | 59.2M | -2.7x | --- |
IR-Med Inc | 58.7M | -20.1x | --- |
Company Information
Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.
Contact Information
- Headquarters
- 1350 S. Loop RoadALAMEDA, CA, United States 94502
- Phone
- 415-506-8462
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Gregg Williams
- Chief Executive Officer, Director
- Adam Mendelsohn
- Chief Financial Officer
- Brigid Makes
- Chief Operating Officer
- Truc Le
- Vice President - Operations
- Ted Randolph
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $79.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.17 |
EPS | $-0.46 |
Book Value | $0.41 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
